ES2261648T3 - Metodo de terapia para el cancer. - Google Patents

Metodo de terapia para el cancer.

Info

Publication number
ES2261648T3
ES2261648T3 ES02714140T ES02714140T ES2261648T3 ES 2261648 T3 ES2261648 T3 ES 2261648T3 ES 02714140 T ES02714140 T ES 02714140T ES 02714140 T ES02714140 T ES 02714140T ES 2261648 T3 ES2261648 T3 ES 2261648T3
Authority
ES
Spain
Prior art keywords
compound
approximately
day
formula
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02714140T
Other languages
English (en)
Spanish (es)
Inventor
Lars Holger Breimer
Kapil Dhingra
Urvashi Hooda Dhingra
Steve Ritland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2261648T3 publication Critical patent/ES2261648T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES02714140T 2001-02-09 2002-02-01 Metodo de terapia para el cancer. Expired - Lifetime ES2261648T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26787401P 2001-02-09 2001-02-09
US267874 2001-02-09

Publications (1)

Publication Number Publication Date
ES2261648T3 true ES2261648T3 (es) 2006-11-16

Family

ID=23020488

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02714140T Expired - Lifetime ES2261648T3 (es) 2001-02-09 2002-02-01 Metodo de terapia para el cancer.

Country Status (17)

Country Link
US (1) US6548531B2 (https=)
EP (1) EP1359979B1 (https=)
JP (1) JP4128872B2 (https=)
KR (1) KR100542069B1 (https=)
CN (1) CN1265786C (https=)
AR (2) AR035429A1 (https=)
AT (1) ATE324145T1 (https=)
AU (1) AU2002246080B2 (https=)
BR (1) BR0206954A (https=)
CA (1) CA2435921C (https=)
DE (1) DE60210926T2 (https=)
DK (1) DK1359979T3 (https=)
ES (1) ES2261648T3 (https=)
MX (1) MXPA03007036A (https=)
PT (1) PT1359979E (https=)
WO (1) WO2002064214A2 (https=)
ZA (1) ZA200305967B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
JP2004532245A (ja) * 2001-05-15 2004-10-21 ページ ダブル フォーク 癌を治療するための生体影響性化合物の標的送達
JP2004537515A (ja) * 2001-05-15 2004-12-16 フォーク ファーマシューティカルス，インク． ウィルス感染症治療用薬物のターゲッティング送達
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
WO2018092020A1 (en) 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
US6080777A (en) * 1992-01-31 2000-06-27 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
CA2140653A1 (en) * 1992-08-12 1994-03-03 Irene Abraham Protein kinase inhibitors and related compounds combined with taxol
PT1064279E (pt) 1998-03-17 2003-10-31 Hoffmann La Roche Bisindolilmaleimidas substituidas para a inibicao da proliferacao celular
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression

Also Published As

Publication number Publication date
WO2002064214A3 (en) 2003-05-30
AU2002246080C1 (en) 2002-08-28
ZA200305967B (en) 2005-01-26
CN1491126A (zh) 2004-04-21
ATE324145T1 (de) 2006-05-15
DK1359979T3 (da) 2006-08-28
AR098745A2 (es) 2016-06-08
MXPA03007036A (es) 2003-11-18
CN1265786C (zh) 2006-07-26
EP1359979A2 (en) 2003-11-12
PT1359979E (pt) 2006-08-31
WO2002064214A8 (en) 2004-02-19
BR0206954A (pt) 2004-02-25
US20020156118A1 (en) 2002-10-24
JP2004517961A (ja) 2004-06-17
KR20040025894A (ko) 2004-03-26
US6548531B2 (en) 2003-04-15
WO2002064214A2 (en) 2002-08-22
JP4128872B2 (ja) 2008-07-30
AR035429A1 (es) 2004-05-26
EP1359979B1 (en) 2006-04-26
CA2435921C (en) 2009-12-22
DE60210926D1 (de) 2006-06-01
AU2002246080B2 (en) 2006-08-10
CA2435921A1 (en) 2002-08-22
KR100542069B1 (ko) 2006-01-11
DE60210926T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
ES2719052T3 (es) Terapia de combinación con un antibiótico antitumoral
ES2204894T3 (es) Composicion que contiene cisplatino y topotecan como agente antitumoral.
ES2762250T5 (es) Tratamiento combinado del cáncer
RU2162327C2 (ru) Лечение рака и профилактика метастазирования
ES2862340T3 (es) Nuevo uso antitumoral de cabazitaxel
ES2261648T3 (es) Metodo de terapia para el cancer.
TWI386214B (zh) 包含亞砷酸、其鈉鹽及其衍生物之用於泌尿生殖器癌及其轉移之治療的醫藥組合物
ES2268764T3 (es) Combinacion antitumoral de 1,4-dioxido de 3-amino-1,2,4-benzotriazina/paclitaxel/platino.
AU2002246080A1 (en) Method for Cancer Therapy
US10080807B2 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin C
ES2241639T3 (es) Terapia de combinacion que usa un compuesto de pentafluorobencensulfonamidas y platino.
ES2316565T3 (es) Composicion antitumoral que contiene tolueno sulfonamida y su procedimiento de uso.
EP1304111A2 (en) Use of methylol-containing compounds for the treatment of breast cancer
WO2022068918A1 (zh) 包含酸碱中和组合的药物组合物及其应用
ES2393398T3 (es) Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer
CN111407748B (zh) 酪醇在制备治疗脑胶质瘤的药物中的应用
Gupta Treatment of advanced gastric cancer with 5‐fluorouracil versus mitomycin C
RU2019120278A (ru) Виды комбинированной лекарственной терапии с использованием лекарственных препаратов, целенаправленно воздействующих на костную ткань, для лечения костей и заболевания, связанного с костной тканью
CN103877114A (zh) 一种用于胃癌治疗含有卡培他滨的药物组合物
MXPA05003625A (es) Terapia de combinacion con gencitabina y zd6126.
CN101181233A (zh) 一种治疗实体肿瘤的吉马替康缓释植入剂